Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Short-term Investments: 2021-2025

Historic Short-term Investments for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $177.2 million.

  • Kiniksa Pharmaceuticals International's Short-term Investments rose 40.22% to $177.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $177.2 million, marking a year-over-year increase of 40.22%. This contributed to the annual value of $60.0 million for FY2024, which is 38.99% down from last year.
  • As of Q3 2025, Kiniksa Pharmaceuticals International's Short-term Investments stood at $177.2 million, which was up 53.13% from $115.7 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's Short-term Investments' 5-year high stood at $177.2 million during Q3 2025, with a 5-year trough of $10.0 million in Q3 2021.
  • For the 3-year period, Kiniksa Pharmaceuticals International's Short-term Investments averaged around $104.0 million, with its median value being $106.9 million (2023).
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Short-term Investments crashed by 42.95% in 2022, and later skyrocketed by 233.52% in 2023.
  • Kiniksa Pharmaceuticals International's Short-term Investments (Quarterly) stood at $59.7 million in 2021, then grew by 13.66% to $67.9 million in 2022, then skyrocketed by 44.96% to $98.4 million in 2023, then slumped by 38.99% to $60.0 million in 2024, then surged by 40.22% to $177.2 million in 2025.
  • Its Short-term Investments was $177.2 million in Q3 2025, compared to $115.7 million in Q2 2025 and $111.2 million in Q1 2025.